PET Imaging of MMP Activation in AAA: Clinical Component

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Washington University School of Medicine
Study ID
NCT07473102
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Abdominal Aortic Aneurysm

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Cu-64-RYM2 — DRUG
    PET/CT scan
  • PET imaging using Cu-64 — DRUG
    PET/CT at different timepoints

Study Details

A first-in-human evaluation of \[64Cu\]-RYM2 with PET/CT will be performed to: a) assess its safety, biodistribution, and radiation dosimetry in normal volunteers (WU) and; b) in AAA patients undergoing surgery (WU and Yale), evaluate radiotracer pharmacodynamics and correlate PET imaging characteristics (WU) with ex vivo tissue measurements (Yale).

Key Dates

Start date
Nov 3, 2025
Status verified
Mar 2026
Primary completion
Mar 31, 2027
Completion
Mar 31, 2027

Study Design

Enrollment
28 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Other: dosimetry and AAA patients
    Patients who have abdominal aortic aneurysm and healthy volunteers

Primary Outcome Measure

Verification Cu-64RYM2-2 signal in AAA segments. This will be performed by measuring Standard Uptake Values obtained from analysis of the Cu-64RYM2 images, in AAA patients. [ Time Frame: 2 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Washington University School of MedicineSt LouisMissouri63110
Kitty Harrison, RN, BSN
[email protected]
314-747-0183
Robert Gropler, MD
314-747-0183
Robert Gropler, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in St Louis, MO

By research site
Washington University School of Medicine· St Louis, MO

Related Studies